The final overall analysis showed that first-line pembrolizumab plus trastuzumab and chemotherapy provided a statistically significant and clinically meaningful improvement in OS vs pembrolizumab plus trastuzumab and chemotherapy, in all patients with unresectable, HER2+ metastatic GC/GEJC. Here, ERBB2 is linked to gastric cancer.